- Home >
- Clinicals Trials >
- TAS6417-301
Retour à la liste des essais cliniquesLung cancer
TAS6417-301
Randomized, Controlled, Open-label, Phase 3, Global Multi-;Center Trial to Assess the Efficacy and Safety of Zipalertinib;plus Chemotherapy versus Chemotherapy alone, in Patients;with Previously Untreated, Locally Advanced or Metastatic;Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with;Epidermal Growth Factor Receptor (EGFR) Exon 20;Insertion (ex20ins) Mutations.
- Ouvert à Paris depuis le : 27/06/2024
- Public cible : Adult
- Phase : Phase III
Description de l'essai
To determine the recommended dose of;zipalertinib in combination with;pemetrexed and a platinum agent to be;studied in the Phase 3 portion of the study;À Incidence of dose-limiting toxicities (DLTs) graded;according to the NCI-Common Terminology Criteria of;Adverse Events (CTCAE) v5.0 during Cycle 1.
Url of the trialInvestigateur principal
